Company intelligence / Profile preview
Instituto Bioclon S.A. de C.V.
Cuautitlán / Mexico City / Santa María Huecatitla, Estado de México / Ciudad de México, Mexicobioclon.com.mx ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Instituto Bioclon specializes in the research, development, and manufacture of F(ab')2-based antivenoms for snakebites and arachnid envenomations. The company has received FDA approval for two drugs—ANAVIP® and ANASCORP®—commercialized in the US by Rare Disease Therapeutics Inc., with additional products approved or pending approval in Mexico. Clinical trials are ongoing for further indications such as black widow spider bites.
- Therapeutic areas
- Other
- Modalities
- F(ab')2 antibody fragments (antivenoms)Antitoxins
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Rare Disease Therapeutics Inc. – commercialization partner in the United States for ANAVIP® and ANASCORP®.
Beyond the preview
Go deeper on Instituto Bioclon S.A. de C.V..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Instituto Bioclon S.A. de C.V..